Is dyslipidaemia important if we control glycaemia?

Atherosclerosis Supplements

Volumn 6, Issue 3 SPEC. ISS., 2005, Pages 3-10

  Schernthaner, Guntram ^a  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

Coronary heart disease; Dyslipidaemia; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ATORVASTATIN; FIBRIC ACID DERIVATIVE; GLIBENCLAMIDE; GLICLAZIDE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; PRAVASTATIN; ROSIGLITAZONE; SIMVASTATIN; SULFONYLUREA;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE CONTROL; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INSULIN TREATMENT; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; METABOLIC SYNDROME X; MORBIDITY; MORTALITY; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RHABDOMYOLYSIS; RISK REDUCTION;

EID: 23744448138     PISSN: 15675688     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2005.06.001     Document Type: Conference Paper

References (44)

1. J.A. Beckman, M.A. Creager, and P. Libby Diabetes and atherosclerosis: epidemiology, pathophysiology, and management JAMA 287 2002 2570 2581
2. R. Holman The UKPDS: implications for the dyslipidaemic patient Acta Diabetol 38 Suppl 1 2001 S9 S14
3. P. Gaede, P. Vedel, and N. Larsen Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes N Engl J Med 348 2003 383 393
4. J. Kaukua, A. Turpeinen, M. Uusitupa, and L. Niskanen Clustering of cardiovascular risk factors in type 2 diabetes mellitus: prognostic significance and tracking Diab Obes Metab 3 2001 17 23
5. G. Schernthaner, G.M. Kostner, H. Dieplinger, R. Prager, and I. Muhlhauser Apolopoproteins (A-I, A-II, B), Lp(a) lipoprotein and lecithin: cholesterol acyltransferase activity in diabetes mellitus Atherosclerosis 49 1983 277 293
6. UK Prospective Diabetes Study 27 Plasma lipids and lipoproteins at diagnosis of NIDDM by age and sex Diab Care 20 1997 1683 1687
7. K. Pyorala, S. Lehto, and D. De Bacquer Risk factor management in diabetic and non-diabetic patients with coronary heart disease. Findings from the EUROASPIRE I AND II surveys Diabetologia 47 2004 1257 1265
8. G.M. Rosano, C. Vitale, A. Silvestri, and M. Fini Hormone replacement therapy and cardioprotection: the end of the tale? Ann NY Acad Sci 997 2003 351 357
9. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 352 1998 837 853
10. R.C. Turner, H. Millns, and H.A. Neil Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23) Br Med J 316 1998 823 828
11. R.A. DeFronzo, A.M. Goodman The Multicenter Metformin Study Group Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus N Engl J Med 333 1995 541 549
12. J.P. van Wijk, E.J. de Koning, E.P. Martens, and T.J. Rabelink Thiazolidinediones and blood lipids in type 2 diabetes Arterioscler Thromb Vasc Biol 23 2003 1744 1749
13. G. Schernthaner, D.R. Matthews, B. Charbonnel, M. Hanefeld, and P. Brunetti Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial J Clin Endocrin Metab 89 2004 6068 6076
14. B. Charbonnel, D.R. Matthews, G. Schernthaner, M. Hanefeld, and P. Brunetti Long-term efficacy and safety of pioglitazone versus gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial Diab Med 22 2005 399 405
15. M. Hanefeld, P. Brunetti, G.H. Schernthaner, D.R. Matthews, B.H. Charbonnel Quartet Study Group One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes Diab Care 27 2004 141 147
16. D.R. Matthews, B.H. Charbonnel, M. Hanefeld, P. Brunetti, and G. Schernthaner Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study Diab Metab Res Rev 21 2005 167 174
17. S. Kudlacek, and G. Schernthaner The effect of insulin treatment on HbA1c, body weight and lipids in type 2 diabetic patients with secondary-failure to sulfonylureas. A five year follow-up study Horm Metab Res 24 1992 478 483
18. H. Yki-Jarvinen, L. Ryysy, and M. Kauppila Effect of obesity on the response to insulin therapy in noninsulin-dependent diabetes mellitus J Clin Endocrinol Metab 82 1997 4037 4043
19. N. Emanuele, N. Azad, and C. Abraira Effect of intensive glycemic control on fibrinogen, lipids, and lipoproteins: Veterans Affairs Cooperative Study in Type II Diabetes Mellitus Arch Int Med 158 1998 2485 2490
20. The Diabetes Control and Complications Trial (DCCT) Research Group Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial Am J Cardiol 75 1995 894 903
21. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
22. P.M. Ridker, N. Rifai, M.A. Pfeffer, F. Sacks, and E. Braunwald Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators Circulation 100 1999 230 235
23. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1998 1349 1357
24. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial Lancet 361 2003 2005 2016
25. H.M. Colhoun, D.J. Betteridge, P.N. Durrington CARDS Investigators Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 6896
26. J.L. Chiasson, R.G. Josse STOP-NIDDM Trial Research Group Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial JAMA 290 2003 486 494
27. V. Papademetriou, L.B. Piller ALLHAT Collaborative Research Group Characteristics and lipid distribution of a large, high-risk, hypertensive population: the lipid-lowering component of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) J Clin Hypertens 5 2003 377 384
28. S. Yusuf, P. Sleight, and J. Pogue Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators N Engl J Med 342 2000 145 153
29. Lars H. Lindholm, Hans Ibsen, and Björn Dahlöf Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 2002 1004 1010
30. J. Tuomilehto, D. Rastenyte, and W.H. Birkenhager Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators N Engl J Med 340 1999 677 684
31. P.S. Sever, B. Dahlof ASCOT Investigators Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 2003 1149 1158
32. Final report on the aspirin component of the ongoing Physicians' Health Study. Steering Committee of the Physicians' Health Study Research Group N Engl J Med 321 1989 129 135
33. Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation J Hypertens 19 Suppl 4 2001 S21 S28
34. B. Charbonnel, J. Dormandy PROactive Study Group The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetes? Study design and baseline characteristics of 5238 patients Diab Care 27 2004 1647 1653
35. G. Viberti, S.E. Kahn, and D.A. Greene A diabetes outcome progression trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes Diab Care 25 2002 1737 1743
36. P.D. Home, S. Pocock, H. Beck-Nielsen The RECORD Study Group Diabetologia 47 Suppl 1 2004 A262
37. S. Halimi, G. Charpentier, and A. Grimaldi Effect on compliance, acceptability of blood glucose self-monitoring and HbA(1c) of a self-monitoring system developed according to patient's wishes. The ACCORD study Diab Metab 27 2001 681 687
38. S.J. Beaton, S.S. Nag, and M.J. Gunter Adequacy of glycemic, lipid, and blood pressure management for patients with diabetes in a managed care setting Diab Care 27 2004 694 698
39. S.M. Haffner, C.M. Alexander, and T.J. Cook Reduced coronary events in simvastatin-treated patients with coronary heart disease and diabetes or impaired fasting glucose levels: subgroup analyses in the Scandinavian Simvastatin Survival Study Arch Int Med 159 1999 2661 2667
40. J.R. Downs, M. Clearfield AFCAPS/TexCAPS Research Group Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS JAMA 279 1998 1615 1622
41. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials Lancet 348 1996 1339 1342
42. H.B. Rubins, S.J. Robins, and D. Collins Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol N Engl J Med 341 1999 410 418
43. UK HDL-C Consensus Group Role of fibrates in reducing coronary risk: a UK consensus Curr Med Res Opin 20 2004 241 247
44. D.J. Graham, J.A. Staffa, and D. Shatin Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs JAMA 292 2004 2585 2590